Seminars & Events
Thursday, September 11, 2014: Dr. Bevil Conway (Wellesley College) will speak on his research in visual neuroscience and color at 4:30 pm in Goodpaster Hall 195.
Monday, October 27, 2014: Dr. Todd Gould (University of Maryland Baltimore) will speak on "Genes to behaviors to treatments in bipolar disorder" at 4:45 pm in Goodpaster Hall 195.Friday, December 5, 2014: Dr. Brian Mathur (University of Maryland Baltimore) will speak on "Braking bad: Aberrant inhibitory neurotransmission in addiction" at 3:00 pm in Goodpaster Hall 195.
Tracy, Megan (2011). Investigating the efficacy of antipsychotic drug treatment on an animal model of schizophrenia. (Mentor: A. Bailey)
Schizophrenia is a disease that is difficult to study and understand due to its variety of symptoms and difficulty to fully treat. The most common treatment for the symptoms of schizophrenia is psychopharmaceutical therapy. Olanzapine is an atypical antipsychotic that is often prescribed for schizophrenia in adults and adolescents. Fifty-six long evans rats were used to test the effects of adolescent olanzapine administration in the NVHL animal model of schizophrenia. The animals’ play behavior was tested during adolescence while they were receiving either olanzapine or vehicle in their drinking water. In adulthood, the rats were tested for disrupted sensory gating and hyperlocomotion. The animals did not show significant differences in the prepulse inhibition task or the hyperlocomotion task. These results suggest that a different dose of olanzapine is necessary to see differences between the animal groups. There were significant differences seen during the adolescent play behavior, showing significantly increased play behavior in the control animals.